Vaccine (mRNA vaccine) · Immune activation · developed by BioNTech
BNT163 is an antiviral RNA vaccine given by intramuscular injection for active immunization against herpes simplex virus type 2 (HSV-2). It is studied in genital herpes simplex type 2 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05432583 | Phase 1 | Genital Herpes Simplex Type 2 | Active not recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Genital Herpes Simplex Type 2
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →